ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

A small preliminary study showed that adding pioglitazone to imatinib therapy might have a favorable impact on residual disease in chronic myeloid leukemia, as measured by conversion to molecular response 4.5.

Patients with CML who have higher proportions of natural killer immune cells, and more mature natural killer cells, fare better when discontinuing therapy with imatinib.

Many patients with stable CML may be able to safely decrease their dose of tyrosine kinase inhibitor to half of the standard dose and improve TKI-related side effects, according to the results of the DESTINY trial.

Cessation of tyrosine kinase inhibitor therapy may be possible in chronic myeloid leukemia patients with deep molecular response, according to the results of the Euro-Ski trial.

According to a long-term follow-up analysis of a phase I/II trial, bosutinib provides durable responses and a favorable toxicity profile in patients with chronic phase CML who are resistant/intolerant to other tyrosine kinase inhibitors.

Expression levels of CD62L and related immunologic markers are correlated with treatment responses and outcome in patients with CML, according to a new analysis. The markers could have prognostic value if validated in other cohorts.

Patients with chronic myeloid leukemia with a history of prior malignancies generally fare as well as those without such a history, according to a new study.

Pages

Subscribe to Chronic Myeloid Leukemia on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.